CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV gastric cancer (GC).Qiang Xue, Han Liang, Xiaona Wang et al.|Journal of Clinical Oncology|2021Cited by 6